血栓・止血バイオマーカーの世界市場

血栓・止血バイオマーカーの世界市場は2030年までに72億米ドルに到達

2024年に55億米ドルと推定される血栓・止血バイオマーカーの世界市場は、2024年から2030年にかけてCAGR 4.8%で成長し、2030年には72億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである分析装置は、CAGR 5.5%を記録し、分析期間終了までに51億米ドルに達すると予測されます。試薬・消耗品セグメントの成長率は、分析期間中CAGR 3.0％と推定されます。

米国市場は15億米ドルと推定・中国はCAGR 8.8％で成長予測

米国の血栓・止血バイオマーカー市場は、2024年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.8%で推移し、2030年には15億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と3.8%と予測されています。欧州では、ドイツがCAGR 2.8%で成長すると予測されています。

血栓・止血バイオマーカー市場の動向と促進要因のまとめ

血栓・止血バイオマーカーはどのように精密医療と血液疾患管理を進めているのか？

血栓・止血バイオマーカーは、血液凝固障害、脳卒中、心血管疾患の早期診断、予後予測、管理において極めて重要な役割を果たしています。これらのバイオマーカーは、臨床医が凝固活性を評価し、凝固亢進状態を検出し、抗凝固療法の効果をモニターするのに役立っています。血栓性疾患の有病率の増加、個別化医療に対する需要の高まり、バイオマーカーに基づく診断の進歩が市場成長の原動力となっています。さらに、AIを搭載した診断プラットフォームやポイントオブケア（POC）検査の登場により、リアルタイムのモニタリングや治療の最適化が向上しています。しかし、バイオマーカーアッセイの標準化、規制承認の複雑さ、新興市場における高度な診断技術へのアクセス制限などの課題は依然としてハードルとなっています。プレシジョン・メディシンが進化し続ける中、血栓・止血バイオマーカーは抗凝固管理と血栓症リスク評価の未来をどのように再構築するのだろうか？

血栓・止血バイオマーカーを前進させる技術革新とは？

高感度バイオマーカーアッセイの開発、AIによる予測モデリング、次世代シーケンサー（NGS）に基づく血液凝固解析は、血栓症診断の精度と信頼性を高めています。マイクロ流体ベースのラボオンチップ装置は、迅速な血液凝固検査を可能にし、早期発見を向上させ、病院の負担を軽減しています。AIを活用した診断アルゴリズムは、凝固バイオマーカーの膨大なデータセットを解析することで、患者のリスク層別化を精緻化しています。さらに、マルチプレックスバイオマーカーパネルによって包括的な血液凝固障害の評価が容易になり、治療の意思決定や個別化治療戦略が向上しています。

なぜ血栓・止血バイオマーカーの需要が増加しているのか？

深部静脈血栓症（DVT）、肺塞栓症、心房細動の世界の発生率の上昇が、高度なバイオマーカーに基づく診断の需要を促進しています。高齢化人口の増加、抗凝固療法の採用増加、迅速な脳卒中リスク評価の必要性が、市場拡大にさらに拍車をかけています。さらに、COVID-19の大流行は、血栓性合併症のモニタリングにおける凝固バイオマーカーの重要性を浮き彫りにし、この分野への研究や投資を加速させています。

血栓・止血バイオマーカー市場の成長を促進する要因は？

精密診断の進歩、心血管バイオマーカー研究への資金提供の増加、POC凝固検査に対する需要の高まり、新規バイオマーカーベースのアッセイに対する規制当局の承認拡大などにより、市場は拡大しています。ヘルスケアシステムが早期発見と個別化治療戦略を優先する中、血栓・止血バイオマーカーは最新の医療診断において重要な役割を果たすと期待されています。

セグメント

製品タイプ（Dダイマー、抗トロンビンIII、プラスミノーゲン、可溶性フィブリン、セレクチン、第VIII因子、PT、APTT、フィブリノーゲン、その他）、最終用途（深部静脈血栓症、肺塞栓症、播種性血管内凝固症候群、その他）、病院・クリニック、学術研究機関、診断センター、その他

調査対象企業の例

• Abbott Laboratories
• Alere Inc.
• Axis-Shield Diagnostics Ltd.
• Beckman Coulter Inc.
• Becton, Dickinson and Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• BioMedica Diagnostics Inc.
• Chrono-Log Corporation
• Danaher Corporation
• Diazyme Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols, S.A.
• Helena Laboratories Corporation
• HemoSonics LLC
• HORIBA Ltd.
• Instrumentation Laboratory（Werfen）
• Medtronic plc
• Nihon Kohden Corporation
• QuidelOrtho Corporation
• Sekisui Diagnostics LLC
• Siemens Healthineers AG

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Thrombosis and Hemostasis Biomarkers Market to Reach US$7.2 Billion by 2030

The global market for Thrombosis and Hemostasis Biomarkers estimated at US$5.5 Billion in the year 2024, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Analyzers, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Reagents & Consumables segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.8% CAGR

The Thrombosis and Hemostasis Biomarkers market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Thrombosis and Hemostasis Biomarkers Market Trends & Drivers Summarized

How Are Thrombosis and Hemostasis Biomarkers Advancing Precision Medicine and Blood Disorder Management?

Thrombosis and hemostasis biomarkers are playing a pivotal role in the early diagnosis, prognosis, and management of blood clotting disorders, stroke, and cardiovascular diseases. These biomarkers help clinicians assess coagulation activity, detect hypercoagulable states, and monitor anticoagulant therapy efficacy. The increasing prevalence of thrombotic disorders, rising demand for personalized medicine, and advancements in biomarker-based diagnostics are driving market growth. Additionally, the emergence of AI-powered diagnostic platforms and point-of-care (POC) testing is improving real-time monitoring and treatment optimization. However, challenges such as standardization of biomarker assays, regulatory approval complexities, and limited accessibility to advanced diagnostic technologies in emerging markets remain hurdles. As precision medicine continues to evolve, how will thrombosis and hemostasis biomarkers reshape the future of anticoagulation management and thrombosis risk assessment?

What Technological Innovations Are Advancing Thrombosis and Hemostasis Biomarkers?

The development of high-sensitivity biomarker assays, AI-driven predictive modeling, and next-generation sequencing (NGS)-based blood clotting analysis is enhancing the accuracy and reliability of thrombosis diagnostics. Microfluidic-based lab-on-a-chip devices are enabling rapid blood coagulation testing, improving early detection and reducing hospital burden. AI-powered diagnostic algorithms are refining patient risk stratification by analyzing vast datasets of coagulation biomarkers. Additionally, multiplex biomarker panels are facilitating comprehensive clotting disorder assessments, improving therapeutic decision-making and personalized treatment strategies.

Why Is the Demand for Thrombosis and Hemostasis Biomarkers Increasing?

The rising global incidence of deep vein thrombosis (DVT), pulmonary embolism, and atrial fibrillation is driving demand for advanced biomarker-based diagnostics. The growing aging population, increasing adoption of anticoagulant therapies, and the need for rapid stroke risk assessment are further fueling market expansion. Additionally, the COVID-19 pandemic underscored the importance of coagulation biomarkers in monitoring thrombotic complications, accelerating research and investment in this field.

What Factors Are Driving the Growth of the Thrombosis and Hemostasis Biomarkers Market?

The market is expanding due to advancements in precision diagnostics, increasing funding for cardiovascular biomarker research, rising demand for POC coagulation testing, and growing regulatory approvals for novel biomarker-based assays. As healthcare systems prioritize early detection and personalized treatment strategies, thrombosis and hemostasis biomarkers are expected to play a crucial role in modern medical diagnostics.

SCOPE OF STUDY:

The report analyzes the Thrombosis and Hemostasis Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Analyzers, Reagents & Consumables); Test Location (Clinical Laboratory Tests, Point-of-Care Tests); Test Type (D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin, Selectins, Factor VIII, PT, APTT, Fibrinogen, Others); Application (Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation, Others); End-Use (Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Alere Inc.
• Axis-Shield Diagnostics Ltd.
• Beckman Coulter Inc.
• Becton, Dickinson and Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• BioMedica Diagnostics Inc.
• Chrono-Log Corporation
• Danaher Corporation
• Diazyme Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols, S.A.
• Helena Laboratories Corporation
• HemoSonics LLC
• HORIBA Ltd.
• Instrumentation Laboratory (Werfen)
• Medtronic plc
• Nihon Kohden Corporation
• QuidelOrtho Corporation
• Sekisui Diagnostics LLC
• Siemens Healthineers AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Thrombosis and Hemostasis Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Thromboembolic Disorders Drives Demand for Diagnostic Biomarkers
  • Advancements in D-Dimer and Fibrinogen Testing Technologies Enhance Clinical Accuracy
  • Integration of Biomarker Panels in Point-of-Care Devices Improves Early Risk Stratification
  • Expansion of Anticoagulant Therapy Monitoring Supports Biomarker Use in Treatment Management
  • Growing Focus on Predictive Biomarkers in Cardiovascular Risk Assessment Fuels R&D
  • Increasing Adoption in ICU, ER, and Surgical Settings Boosts Biomarker Utility
  • Regulatory Approvals for Multi-Analyte Panels Expand Commercial Diagnostic Offerings
  • Personalized Medicine Trends Accelerate Development of Patient-Specific Biomarker Algorithms
  • AI-Powered Interpretation of Hemostasis Profiles Supports Clinical Decision-Making
  • Growth in Clinical Trials for Novel Antithrombotics Elevates Biomarker Demand in Drug Development
  • Public-Private Partnerships in Biomarker Validation Improve Standardization Across Labs
  • Expansion of Coagulation Testing in Emerging Markets Drives Decentralized Diagnostic Adoption
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Thrombosis and Hemostasis Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Thrombosis and Hemostasis Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for PT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for PT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for PT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for APTT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for APTT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for APTT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Fibrinogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for D-Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for D-Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for D-Dimer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Anti-Thrombin III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Anti-Thrombin III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Anti-Thrombin III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Plasminogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Plasminogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Plasminogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Soluble Fibrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Soluble Fibrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Soluble Fibrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Selectins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Selectins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Selectins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Pulmonary Embolism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Disseminated Intravascular Coagulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Disseminated Intravascular Coagulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Disseminated Intravascular Coagulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 62: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 65: World Recent Past, Current & Future Analysis for Clinical Laboratory Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: World Historic Review for Clinical Laboratory Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: World 15-Year Perspective for Clinical Laboratory Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 68: World Recent Past, Current & Future Analysis for Point-of-Care Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: World Historic Review for Point-of-Care Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: World 15-Year Perspective for Point-of-Care Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 71: USA Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: USA 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 74: USA Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: USA Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: USA 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 77: USA Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: USA Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: USA 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 80: USA Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: USA Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: USA 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 83: USA Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: USA Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: USA 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Canada 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 89: Canada Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Canada Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Canada 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 92: Canada Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Canada Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Canada 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 95: Canada Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Canada Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Canada 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 98: Canada Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Canada Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Canada 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• JAPAN
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 101: Japan Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Japan Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Japan 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 104: Japan Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Japan Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Japan 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 107: Japan Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Japan Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Japan 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 110: Japan Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Japan Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Japan 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 113: Japan Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Japan Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Japan 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• CHINA
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 116: China Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: China Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: China 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 119: China Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: China Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: China 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 122: China Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: China Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: China 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 125: China Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: China Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: China 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 128: China Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: China Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: China 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• EUROPE
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 131: Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 132: Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 134: Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 137: Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 140: Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 143: Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Europe Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 146: Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• FRANCE
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 149: France Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: France Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: France 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 152: France Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: France Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: France 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 155: France Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: France Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: France 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 158: France Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: France Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: France 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 161: France Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: France Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: France 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• GERMANY
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 164: Germany Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Germany Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Germany 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 167: Germany Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Germany Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Germany 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 170: Germany Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Germany Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Germany 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 173: Germany Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Germany Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Germany 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 176: Germany Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Germany Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Germany 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 179: Italy Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Italy Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Italy 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 182: Italy Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Italy Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Italy 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 185: Italy Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Italy Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Italy 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 188: Italy Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Italy Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Italy 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 191: Italy Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Italy Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Italy 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 194: UK Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UK Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: UK 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 197: UK Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UK Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: UK 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 200: UK Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UK Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: UK 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 203: UK Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UK Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: UK 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 206: UK Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: UK Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: UK 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 209: Spain Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Spain Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Spain 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 212: Spain Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Spain Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Spain 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 215: Spain Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Spain Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Spain 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 218: Spain Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Spain Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Spain 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 221: Spain Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Spain Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Spain 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 224: Russia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Russia Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Russia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 227: Russia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Russia Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Russia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 230: Russia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Russia Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Russia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 233: Russia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Russia Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Russia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 236: Russia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Russia Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Russia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Europe Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Europe Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Europe Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Europe 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 255: Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 260: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 263: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 266: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 269: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 272: Australia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Australia Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Australia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 275: Australia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Australia Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Australia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 278: Australia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Australia Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Australia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 281: Australia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Australia Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Australia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 284: Australia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Australia Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Australia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• INDIA
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 287: India Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: India Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: India 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 290: India Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: India Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: India 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 293: India Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: India Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: India 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 296: India Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: India Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: India 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 299: India Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: India Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: India 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 302: South Korea Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: South Korea Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: South Korea 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 305: South Korea Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: South Korea Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: South Korea 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 308: South Korea Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: South Korea Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: South Korea 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 311: South Korea Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: South Korea Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: South Korea 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 314: South Korea Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: South Korea Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: South Korea 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 329: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Asia-Pacific Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Asia-Pacific 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 332: Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 333: Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 335: Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 338: Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 341: Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 344: Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 347: Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 350: Argentina Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Argentina Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Argentina 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 353: Argentina Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Argentina Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Argentina 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 356: Argentina Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Argentina Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Argentina 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 359: Argentina Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Argentina Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Argentina 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 362: Argentina Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Argentina Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Argentina 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 365: Brazil Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Brazil Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Brazil 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 368: Brazil Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Brazil Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Brazil 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 371: Brazil Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Brazil Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Brazil 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 374: Brazil Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Brazil Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Brazil 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 377: Brazil Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Brazil Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Brazil 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 380: Mexico Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Mexico Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Mexico 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 383: Mexico Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Mexico Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Mexico 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 386: Mexico Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Mexico Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Mexico 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 389: Mexico Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Mexico Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Mexico 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 392: Mexico Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Mexico Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Mexico 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 407: Rest of Latin America Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Rest of Latin America Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Rest of Latin America 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 410: Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 411: Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 413: Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 416: Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 419: Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 421: Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 422: Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 424: Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 425: Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 427: Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 428: Iran Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Iran Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 430: Iran 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 431: Iran Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Iran Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 433: Iran 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 434: Iran Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Iran Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 436: Iran 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 437: Iran Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Iran Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 439: Iran 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 440: Iran Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Iran Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 442: Iran 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 443: Israel Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Israel Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 445: Israel 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 446: Israel Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Israel Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 448: Israel 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 449: Israel Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Israel Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 451: Israel 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 452: Israel Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 453: Israel Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 454: Israel 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 455: Israel Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 456: Israel Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 457: Israel 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 459: Saudi Arabia Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 460: Saudi Arabia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 461: Saudi Arabia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 462: Saudi Arabia Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 463: Saudi Arabia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 464: Saudi Arabia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 465: Saudi Arabia Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 466: Saudi Arabia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 467: Saudi Arabia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 468: Saudi Arabia Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 469: Saudi Arabia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 470: Saudi Arabia Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 471: Saudi Arabia Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 472: Saudi Arabia 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 473: UAE Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 474: UAE Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 475: UAE 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 476: UAE Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 477: UAE Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 478: UAE 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 479: UAE Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 480: UAE Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 481: UAE 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 482: UAE Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 483: UAE Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 484: UAE 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 485: UAE Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 486: UAE Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 487: UAE 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 489: Rest of Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 490: Rest of Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 491: Rest of Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Rest of Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 493: Rest of Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 494: Rest of Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Rest of Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 496: Rest of Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 497: Rest of Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 498: Rest of Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 499: Rest of Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 500: Rest of Middle East Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 501: Rest of Middle East Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 502: Rest of Middle East 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030
• AFRICA
  • Thrombosis and Hemostasis Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 503: Africa Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 504: Africa Historic Review for Thrombosis and Hemostasis Biomarkers by Product - Analyzers and Reagents & Consumables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 505: Africa 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Product - Percentage Breakdown of Value Sales for Analyzers and Reagents & Consumables for the Years 2015, 2025 & 2030
  • TABLE 506: Africa Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 507: Africa Historic Review for Thrombosis and Hemostasis Biomarkers by Test Type - Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 508: Africa 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Type - Percentage Breakdown of Value Sales for Factor VIII, PT, APTT, Fibrinogen, Other Test Types, D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin and Selectins for the Years 2015, 2025 & 2030
  • TABLE 509: Africa Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 510: Africa Historic Review for Thrombosis and Hemostasis Biomarkers by Application - Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 511: Africa 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 512: Africa Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 513: Africa Historic Review for Thrombosis and Hemostasis Biomarkers by End-Use - Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 514: Africa 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research Institutes, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 515: Africa Recent Past, Current & Future Analysis for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 516: Africa Historic Review for Thrombosis and Hemostasis Biomarkers by Test Location - Clinical Laboratory Tests and Point-of-Care Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 517: Africa 15-Year Perspective for Thrombosis and Hemostasis Biomarkers by Test Location - Percentage Breakdown of Value Sales for Clinical Laboratory Tests and Point-of-Care Tests for the Years 2015, 2025 & 2030

IV. COMPETITION